167 related articles for article (PubMed ID: 18494155)
21. Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate.
Lertnawapan R; Chonprasertsuk S; Siramolpiwat S
Int J Rheum Dis; 2019 Feb; 22(2):214-221. PubMed ID: 30565876
[TBL] [Abstract][Full Text] [Related]
22. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis.
Ashton RE; Millward-Sadler GH; White JE
J Invest Dermatol; 1982 Oct; 79(4):229-32. PubMed ID: 7130740
[TBL] [Abstract][Full Text] [Related]
23. [Methotrexate, liver and rheumatoid arthritis in tropical areas].
Diouf ML; Diallo S; Mbengue M; Moreira-Diop T
Sante; 2001; 11(3):195-200. PubMed ID: 11641084
[TBL] [Abstract][Full Text] [Related]
24. Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis.
Nohlgård C; Rubio CA; Kock Y; Hammar H
J Am Acad Dermatol; 1993 Jan; 28(1):40-5. PubMed ID: 7678843
[TBL] [Abstract][Full Text] [Related]
25. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?
Thomas JA; Aithal GP
Am J Clin Dermatol; 2005; 6(6):357-63. PubMed ID: 16343024
[TBL] [Abstract][Full Text] [Related]
26. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis.
Zachariae H; Aslam HM; Bjerring P; Søgaard H; Zachariae E; Heickendorff L
J Am Acad Dermatol; 1991 Jul; 25(1 Pt 1):50-3. PubMed ID: 1880254
[TBL] [Abstract][Full Text] [Related]
27. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate.
Phillips CA; Cera PJ; Mangan TF; Newman ED
J Rheumatol; 1992 Feb; 19(2):229-33. PubMed ID: 1629819
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis.
Shergy WJ; Polisson RP; Caldwell DS; Rice JR; Pisetsky DS; Allen NB
Am J Med; 1988 Dec; 85(6):771-4. PubMed ID: 3195601
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.
Montaudié H; Sbidian E; Paul C; Maza A; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP
J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():12-8. PubMed ID: 21388454
[TBL] [Abstract][Full Text] [Related]
30. Liver damage due to methotrexate in patients with psoriasis.
Dahl MG; Gregory MM; Scheuer PJ
Br Med J; 1971 Mar; 1(5750):625-30. PubMed ID: 5548839
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis.
Maybury CM; Samarasekera E; Douiri A; Barker JN; Smith CH
Br J Dermatol; 2014 Jun; 170(6):1237-47. PubMed ID: 24588075
[TBL] [Abstract][Full Text] [Related]
32. Liver cirrhosis due to methotrexate in a patient with rheumatoid arthritis.
ter Borg EJ; Seldenrijk CA; Timmer R
Neth J Med; 1996 Dec; 49(6):244-6. PubMed ID: 8990864
[TBL] [Abstract][Full Text] [Related]
33. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio.
Lanse SB; Arnold GL; Gowans JD; Kaplan MM
Dig Dis Sci; 1985 Feb; 30(2):104-9. PubMed ID: 3967557
[TBL] [Abstract][Full Text] [Related]
34. Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate?
Kaffenberger BH; Kaffenberger JA; Wong H; Jarjour W; Levin D; Bechtel MA
Int J Dermatol; 2015 Jul; 54(7):752-6. PubMed ID: 26108262
[TBL] [Abstract][Full Text] [Related]
35. Practice gaps. Methotrexate-induced liver toxicity: replacing the liver biopsy.
Strober BE
JAMA Dermatol; 2014 Aug; 150(8):862-3. PubMed ID: 24965863
[No Abstract] [Full Text] [Related]
36. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study.
Martyn-Simmons CL; Rosenberg WM; Cross R; Wong T; Smith CH; Barker JN
Br J Dermatol; 2014 Aug; 171(2):267-73. PubMed ID: 24942271
[TBL] [Abstract][Full Text] [Related]
37. Galactose tolerance test and methotrexate-induced liver fibrosis and cirrhosis in patients with psoriasis.
Lenler-Petersen P; Søgård H; Thestrup-Pedersen K; Zachariae H
Acta Derm Venereol; 1982; 62(5):448-9. PubMed ID: 6183903
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens.
Dahl MG; Gregory MM; Scheuer PJ
Br Med J; 1972 Mar; 1(5801):654-6. PubMed ID: 5015292
[TBL] [Abstract][Full Text] [Related]
39. [Advanced liver fibrosis secondary to methotrexate treatment].
Polo Romero FJ; Blasco Colmenarejo MM; Tirado Miranda R; Navarro Martínez A
Gastroenterol Hepatol; 2003 Nov; 26(9):617-8. PubMed ID: 14642249
[No Abstract] [Full Text] [Related]
40. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?
Aithal GP; Haugk B; Das S; Card T; Burt AD; Record CO
Aliment Pharmacol Ther; 2004 Feb; 19(4):391-9. PubMed ID: 14871278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
